company background image

BeiGene NasdaqGS:BGNE Stock Report

Last Price


Market Cap







05 Oct, 2022


Company Financials +
BGNE fundamental analysis
Snowflake Score
Future Growth2/6
Past Performance0/6
Financial Health5/6

BGNE Stock Overview

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide.

BeiGene, Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for BeiGene
Historical stock prices
Current Share PriceUS$144.27
52 Week HighUS$392.30
52 Week LowUS$118.18
1 Month Change-13.55%
3 Month Change-24.63%
1 Year Change-57.44%
3 Year Change24.51%
5 Year Change33.52%
Change since IPO409.43%

Recent News & Updates

Sep 16

EMA panel recommends extending indication for BeiGene's cancer drug Brukinsa

The European Union drug regulator's human medicines committee has recommended extending the indication for BeiGene's (NASDAQ:BGNE) cancer drug Brukinsa, according to the highlights of their latest meeting released on Friday. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended adopting a new indication for Brukinsa as a monotherapy for the treatment of marginal zone lymphoma (MZL). MZL is the second most common non-Hodgkin's lymphoma (NHL), accounting for about seven to eight percent of all NHL cases. Brukinsa was already approved in the European Union for the treatment of Waldenstrom's macroglobulinaemia, a rare type of cancer that begins in the white blood cells. U.S.-listed shares of BeiGene (BGNE) opened 1.4% lower at $158.43.

Shareholder Returns

BGNEUS BiotechsUS Market

Return vs Industry: BGNE underperformed the US Biotechs industry which returned -20.8% over the past year.

Return vs Market: BGNE underperformed the US Market which returned -18.2% over the past year.

Price Volatility

Is BGNE's price volatile compared to industry and market?
BGNE volatility
BGNE Average Weekly Movement8.1%
Biotechs Industry Average Movement11.1%
Market Average Movement6.9%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: BGNE is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: BGNE's weekly volatility (8%) has been stable over the past year.

About the Company

20108,600John Oyler

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin’s lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company’s clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors.

BeiGene, Ltd. Fundamentals Summary

How do BeiGene's earnings and revenue compare to its market cap?
BGNE fundamental statistics
Market CapUS$14.96b
Earnings (TTM)-US$2.01b
Revenue (TTM)US$1.07b


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BGNE income statement (TTM)
Cost of RevenueUS$1.78b
Gross Profit-US$714.29m
Other ExpensesUS$1.29b

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)-19.34
Gross Margin-66.84%
Net Profit Margin-187.65%
Debt/Equity Ratio10.7%

How did BGNE perform over the long term?

See historical performance and comparison